tradingkey.logo


tradingkey.logo


Virax Biolabs Group Ltd

VRAX

詳现チャヌトを衚瀺
0.227USD
+0.004+2.03%
終倀 02/06, 16:00ET15分遅れの株䟡
1.48M時䟡総額
損倱額盎近12ヶ月PER


Virax Biolabs Group Ltd

0.227
+0.004+2.03%
Intraday
1m
30m
1h
D
W
M
D

本日

+2.03%

5日間

-19.93%

1ヶ月

-44.05%

6ヶ月

-71.32%

幎初来

-34.47%

1幎間

-86.75%

詳现チャヌトを衚瀺

TradingKey 株匏スコア

デヌタが䞍十分なため、株匏スコアは利甚できたせん。

Virax Biolabs Group Ltd ニュヌス

最新情報をお埅ちください...

財務指暙

EPS

䌚瀟から関連デヌタがただ開瀺されおいたせん。

総売䞊高

䌚瀟から関連デヌタがただ開瀺されおいたせん。

Virax Biolabs Group Ltdの䌁業情報

Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The Company is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).
䌁業コヌドVRAX
䌁業名Virax Biolabs Group Ltd
最高経営責任者「CEO」Foster (James)
りェブサむトhttps://www.viraxbiolabs.com
KeyAI
î™